226 related articles for article (PubMed ID: 32060420)
1. Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.
Wang Y; Liu Y; Bailey C; Zhang H; He M; Sun D; Zhang P; Parkin B; Baer MR; Zheng P; Malek SN; Liu Y
Oncogene; 2020 Apr; 39(14):3015-3027. PubMed ID: 32060420
[TBL] [Abstract][Full Text] [Related]
2. Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells.
Wang Y; Liu Y; Tang F; Bernot KM; Schore R; Marcucci G; Caligiuri MA; Zheng P; Liu Y
Blood; 2014 Aug; 124(7):1127-35. PubMed ID: 24994068
[TBL] [Abstract][Full Text] [Related]
3. Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer.
Bailey CM; Liu Y; Peng G; Zhang H; He M; Sun D; Zheng P; Liu Y; Wang Y
Nanomedicine; 2020 Oct; 29():102278. PubMed ID: 32738299
[TBL] [Abstract][Full Text] [Related]
4. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
5. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Yao Y; Wang L; Zhou J; Zhang X
J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
[TBL] [Abstract][Full Text] [Related]
6. AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.
Yan B; Claxton D; Huang S; Qiu Y
Exp Hematol; 2020 Jul; 87():13-19. PubMed ID: 32569759
[TBL] [Abstract][Full Text] [Related]
7. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
8. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
9. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
[TBL] [Abstract][Full Text] [Related]
10.
George B; Kantarjian H; Baran N; Krocker JD; Rios A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639121
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
[TBL] [Abstract][Full Text] [Related]
12. HIF-1α inhibition by 2-methoxyestradiol induces cell death via activation of the mitochondrial apoptotic pathway in acute myeloid leukemia.
Zhe N; Chen S; Zhou Z; Liu P; Lin X; Yu M; Cheng B; Zhang Y; Wang J
Cancer Biol Ther; 2016 Jun; 17(6):625-34. PubMed ID: 27082496
[TBL] [Abstract][Full Text] [Related]
13. TP53 signal pathway confers potential therapy target in acute myeloid leukemia.
Zhu G; Cai J; Zhong H
Eur J Haematol; 2023 May; 110(5):480-489. PubMed ID: 36692074
[TBL] [Abstract][Full Text] [Related]
14. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.
Prokocimer M; Molchadsky A; Rotter V
Blood; 2017 Aug; 130(6):699-712. PubMed ID: 28607134
[TBL] [Abstract][Full Text] [Related]
15. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Carter BZ; Mak PY; Muftuoglu M; Tao W; Ke B; Pei J; Bedoy AD; Ostermann LB; Nishida Y; Isgandarova S; Sobieski M; Nguyen N; Powell RT; Martinez-Moczygemba M; Stephan C; Basyal M; Pemmaraju N; Boettcher S; Ebert BL; Shpall EJ; Wallner B; Morgan RA; Karras GI; Moll UM; Andreeff M
Blood; 2023 Sep; 142(12):1056-1070. PubMed ID: 37339579
[TBL] [Abstract][Full Text] [Related]
16. Role of p53 in regulation of hematopoiesis in health and disease.
Barajas S; Cai W; Liu Y
Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
[TBL] [Abstract][Full Text] [Related]
17. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
Kojima K
Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia inducible factor 1α expression and effects of its inhibitors in canine lymphoma.
Kambayashi S; Igase M; Kobayashi K; Kimura A; Shimokawa Miyama T; Baba K; Noguchi S; Mizuno T; Okuda M
J Vet Med Sci; 2015 Nov; 77(11):1405-12. PubMed ID: 26050843
[TBL] [Abstract][Full Text] [Related]
19. Current status and new treatment approaches in TP53 mutated AML.
Hunter AM; Sallman DA
Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
[TBL] [Abstract][Full Text] [Related]
20. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
Wong TN; Ramsingh G; Young AL; Miller CA; Touma W; Welch JS; Lamprecht TL; Shen D; Hundal J; Fulton RS; Heath S; Baty JD; Klco JM; Ding L; Mardis ER; Westervelt P; DiPersio JF; Walter MJ; Graubert TA; Ley TJ; Druley T; Link DC; Wilson RK
Nature; 2015 Feb; 518(7540):552-555. PubMed ID: 25487151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
